Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Has results × abemaciclib × Clear all

Phase

Phase 2 19 Phase 1 10 Phase 3 9 Phase 1/2 4 Phase 4 1 Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 7 Cyclophosphamide 7 Paclitaxel 6 Etoposide 6 Drug Therapy 6 Leucovorin 5 Granulocyte Colony-Stimulating Factor 5 Filgrastim 5 Doxorubicin 5 Sirolimus 4 Radiotherapy, Intensity-Modulated 4 Radiotherapy 4 Oxaliplatin 4 Nivolumab 4 Melphalan 4 Immunoglobulin G 4 Gemcitabine 4 Fluorouracil 4 Docetaxel 4 Disulfides 4 Cytarabine 4 Cisplatin 4 Carboplatin 4 Capecitabine 4 Bevacizumab 4 pembrolizumab 3 dexamethasone acetate 3 dexamethasone 21-phosphate 3 auricularum 3 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03706365 2025-04-20

CYCLONE 2

Eli Lilly and Company

Phase 2/3 Active not recruiting

393 enrolled 23 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡